FDA is formalizing RWD as core evidence, enabling “single pivotal trial plus confirmatory evidence” approaches that may ...

This episode of The Ron Lanton Report explores how geography, policy, and capital are converging to redefine where innovation ...

Cell and gene therapies (CGT) continue to advance in the pharmaceutical industry. Despite continued investment in R&D, the ...

In today’s Pharmaceutical Executive Daily, the FDA expands the use of Tzield to young children to delay the onset of stage 3 ...

Pediatric approval leveraged CupidKids pharmacokinetic bridging and safety assessments, with adverse events consistent across ...

Eligibility now includes ages 1–7 years with stage 2 T1D, defined by multiple diabetes autoantibodies plus dysglycemia ...

AbbVie has announced a $1.4 billion investment to build a new pharmaceutical manufacturing campus in North Carolina, ...

Each April, thousands of leaders across the pharmaceutical and life sciences industry converge in Las Vegas for the Asembia ...

Cell and gene therapies (CGT) continue to advance in the pharmaceutical industry. Despite continued investment in R&D, the ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

Integrating GLP-1 therapy into primary care enables clinicians to contextualize weight loss alongside cardiometabolic ...

In March, Pharmaceutical Executive reported on Eli Lilly’s efforts to push back against the availability of compounded GLP-1 ...